Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 1,654.3 million, representing a 3.6% increase compared to RMB 1,596.3 million in 2023[4]. - The net profit attributable to shareholders for the same period was RMB 65.6 million, a decrease of 23.7% from RMB 85.9 million in 2023[4]. - The total assets of the company as of December 31, 2024, were RMB 3,004.9 million, a slight decrease from RMB 3,047.7 million in 2023[4]. - The company reported a net cash outflow from operating activities of RMB 99.6 million, down from RMB 265.0 million in 2023[4]. - The group reported a billable income of RMB 1,582.1 million for owned hospitals, a growth of 2.9% compared to 2023, driven by an increase in outpatient and inpatient visits[18]. - Total operating revenue for 2024 reached RMB 1,654,289,413, an increase of 3.7% compared to RMB 1,596,265,532 in 2023[106]. - Total operating costs for 2024 were RMB 1,549,653,899, up from RMB 1,495,651,128 in 2023, reflecting a growth of 3.6%[106]. - Net profit for 2024 decreased to RMB 50,397,711, down 42% from RMB 86,931,608 in 2023[107]. - Basic and diluted earnings per share for 2024 were both RMB 0.88, compared to RMB 1.15 in 2023[108]. Operational Metrics - The company operated 32 hospitals as of December 31, 2024, maintaining the same number as in 2023, with total operational beds increasing to 11,508 from 11,268[6]. - Revenue from owned hospital operations was RMB 1,517.8 million, an increase of 2.2% from 2023[14]. - The gross profit margin for owned hospitals improved to 25.9%, up from 25.4% in 2023[14]. - The total revenue from inpatient services for the year ended December 31, 2024, was RMB 933.7 million, a 0.4% increase compared to 2023, driven by a 5.6% growth in inpatient bed days due to new acquisitions[22]. - Outpatient revenue for the same period reached RMB 173.5 million, reflecting a 4.9% increase, supported by a 20.1% rise in outpatient visits despite a 12.6% decrease in average spending per visit[22]. - The average occupancy rate for inpatient services improved to 88.4% in 2024 from 85.9% in 2023, with total inpatient bed days increasing to 2,889,163[21]. - The total revenue from pharmaceutical sales was RMB 218.1 million, up 4.6% from RMB 208.4 million in 2023[22]. Research and Development - The company submitted 25 research projects and published 164 academic papers, including 85 SCI papers, showcasing strong research innovation capabilities[10]. - Research and development expenses amounted to RMB 36.5 million, a 12.5% increase from 2023, representing 2.4% of self-owned hospital operating revenue[38]. - Research and development expenses increased to RMB 36,519,661 in 2024, up from RMB 32,466,196 in 2023, indicating a growth of 12.6%[106]. Elderly Care Services - The elderly care business generated approximately RMB 461.9 million in medical revenue, accounting for 30.4% of the company's self-operated hospital revenue[9]. - The company is actively expanding its elderly care services, with six elderly hospitals opened and one health care project under construction[9]. - The total revenue from elderly care inpatient services was RMB 439.7 million, marking a 12.9% increase, attributed to a 23.4% rise in inpatient bed days[26]. - The average expenditure for elderly care outpatient services decreased significantly, leading to a 33.5% drop in outpatient revenue for elderly care[26]. Financial Position and Liabilities - The balance of bank borrowings as of December 31, 2024, was RMB 946.2 million, an increase from RMB 864.7 million as of December 31, 2023, due to repayments of RMB 367.0 million and new borrowings of RMB 448.5 million[69]. - The asset-liability ratio increased to 55.3% as of December 31, 2024, compared to 53.8% as of December 31, 2023[75]. - The company's total liabilities decreased to RMB 1,994,721,479 in 2024 from RMB 2,060,039,035 in 2023[110]. - The total liabilities to equity ratio for 2024 is approximately 1.24, indicating a slight increase from the previous year's ratio[111]. Shareholder Returns and Dividends - The board of directors has proposed a final dividend of RMB 3 per 10 shares, totaling RMB 21.801 million, which represents 33.2% of the net profit attributable to the parent company's shareholders for the reporting period[82]. - The total proposed dividends for the 2024 interim and final periods amount to RMB 32.701 million, accounting for 49.8% of the net profit attributable to the parent company's shareholders[82]. - The proposed final dividend for the year ended December 31, 2024, is RMB 21,801,000, based on 72,670,000 shares, pending shareholder approval[135]. - The company plans to distribute an interim dividend of RMB 10,900,500 for the six months ended June 30, 2024, also based on 72,670,000 shares, subject to approval at the upcoming extraordinary general meeting[135]. Corporate Governance and Compliance - The audit committee reviewed the financial performance for the fiscal year ending December 31, 2024, and confirmed compliance with applicable accounting standards[89]. - The company has adhered to all corporate governance codes during the reporting period[90]. - The financial statements were prepared in accordance with the Enterprise Accounting Standards and based on the going concern principle[96]. - The company has not made any significant changes to its accounting policies that would materially affect its financial position[101]. Employee and Management - The company has a total of 4,869 full-time employees as of December 31, 2024, compared to 4,765 employees as of December 31, 2023, with employee compensation amounting to RMB 644.1 million, up from RMB 607.4 million in 2023[76]. - The average employee compensation, including social insurance and housing fund contributions, is RMB 132.3 thousand per year[76]. - The board of directors includes experienced executives, which may contribute to strategic decision-making and governance[142].
康宁医院(02120) - 2024 - 年度业绩